About pSivida Corp. (NASDAQ:PSDV)
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:PSDV
- CUSIP: N/A
- Web: www.psivida.com/
- Market Cap: $47.25 million
- Outstanding Shares: 39,372,000
- 50 Day Moving Avg: $1.24
- 200 Day Moving Avg: $1.55
- 52 Week Range: $1.03 - $2.45
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.14
- P/E Growth: 0.00
- Annual Revenue: $7.54 million
- Price / Sales: 6.27
- Book Value: $0.34 per share
- Price / Book: 3.53
- EBITDA: ($15,700,000.00)
- Net Margins: -872.47%
- Return on Equity: -189.83%
- Return on Assets: -135.60%
- Current Ratio: 3.35%
- Quick Ratio: 3.35%
- Average Volume: 505,388 shs.
- Beta: 1.37
- Short Ratio: 1.68
Frequently Asked Questions for pSivida Corp. (NASDAQ:PSDV)
What is pSivida Corp.'s stock symbol?
pSivida Corp. trades on the NASDAQ under the ticker symbol "PSDV."
How were pSivida Corp.'s earnings last quarter?
pSivida Corp. (NASDAQ:PSDV) announced its quarterly earnings results on Monday, September, 11th. The company reported ($0.16) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.16). The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.48 million. pSivida Corp. had a negative net margin of 872.47% and a negative return on equity of 189.83%. View pSivida Corp.'s Earnings History.
When will pSivida Corp. make its next earnings announcement?
Where is pSivida Corp.'s stock going? Where will pSivida Corp.'s stock price be in 2017?
5 equities research analysts have issued 1-year target prices for pSivida Corp.'s shares. Their predictions range from $5.00 to $13.00. On average, they anticipate pSivida Corp.'s share price to reach $8.60 in the next year. View Analyst Ratings for pSivida Corp..
Who are some of pSivida Corp.'s key competitors?
Some companies that are related to pSivida Corp. include Galmed Pharmaceuticals (GLMD), Versartis (VSAR), AcelRx Pharmaceuticals (ACRX), ProNAi Therapeutics (SRRA), Affimed N.V. (AFMD), Ophthotech Corporation (OPHT), Ergomed PLC (ERGO), Dipexium Pharmaceuticals (PLXP), Viking Therapeutics (VKTX), ADMA Biologics (ADMA), Aeglea BioTherapeutics (AGLE), Lipocine (LPCN), vTv Therapeutics (VTVT), Applied Genetic Technologies Corporation (AGTC), Ampio Pharmaceuticals (AMPE), Inotek Pharmaceuticals Corporation (ITEK), Aradigm Corporation (ARDM) and Pfenex (PFNX).
Who are pSivida Corp.'s key executives?
pSivida Corp.'s management team includes the folowing people:
- David J. Mazzo Ph.D., Independent Chairman of the Board
- Nancy S. Lurker, President, Chief Executive Officer, Independent Director
- Leonard S. Ross, Vice President - Finance, Principal Financial Officer
- Debora A. Jorn, Executive Vice President - Corporate and Commercial Development
- James J. Barry Ph.D., Independent Director
- Jay S. Duker M.D., Independent Director
- Douglas Evan Godshall M.B.A., Independent Director
- Kristine Peterson, Independent Director
- Michael W. Rogers, Independent Director
How do I buy pSivida Corp. stock?
Shares of pSivida Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is pSivida Corp.'s stock price today?
MarketBeat Community Rating for pSivida Corp. (NASDAQ PSDV)MarketBeat's community ratings are surveys of what our community members think about pSivida Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of pSivida Corp. stock can currently be purchased for approximately $1.20.
Earnings History for pSivida Corp. (NASDAQ:PSDV)Earnings History by Quarter for pSivida Corp. (NASDAQ PSDV)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|9/11/2017||Q4 2017||($0.16)||($0.16)||$0.48 million||$0.70 million||View||N/A|
|5/4/2017||Q3 2017||($0.15)||($0.15)||$0.36 million||$0.59 million||View||Listen|
|11/7/2016||Q1||($0.19)||($0.21)||$0.30 million||$0.28 million||View||Listen|
|9/12/2016||Q4||($0.13)||($0.19)||$2.40 million||$0.30 million||View||Listen|
|5/5/2016||Q3||($0.20)||($0.15)||$1.75 million||$0.32 million||View||N/A|
|11/5/2015||Q116||($0.15)||($0.17)||$0.50 million||$0.47 million||View||N/A|
|9/9/2015||Q415||($0.14)||($0.17)||$0.60 million||$0.41 million||View||N/A|
|11/7/2014||Q3 14||($0.12)||$0.67||$25.30 million||View||N/A|
|5/13/2014||Q314||($0.15)||($0.03)||$0.55 million||$2.00 million||View||N/A|
|2/7/2014||Q214||($0.13)||($0.13)||$430.00 million||$0.59 million||View||N/A|
|9/25/2013||Q413||($0.12)||($0.17)||$0.65 million||$0.49 million||View||N/A|
|2/6/2013||Q2 2013||($0.11)||$0.63 million||$0.59 million||View||Listen|
Earnings Estimates for pSivida Corp. (NASDAQ:PSDV)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for pSivida Corp. (NASDAQ:PSDV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for pSivida Corp. (NASDAQ:PSDV)
Insider Ownership Percentage: 2.59%Insider Trades by Quarter for pSivida Corp. (NASDAQ:PSDV)
Institutional Ownership Percentage: 14.94%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/14/2017||Nancy Lurker||Insider||Buy||56,700||$1.76||$99,792.00|| |
|1/4/2016||Leonard S. Ross||VP||Sell||5,000||$4.70||$23,500.00|| |
|12/22/2015||Leonard S. Ross||VP||Sell||33,950||$5.39||$182,990.50|| |
|12/22/2015||Paul Ashton||CEO||Sell||120,000||$5.39||$646,800.00|| |
|10/1/2014||Paul Ashton||CEO||Sell||10,000||$4.27||$42,700.00|| |
|9/2/2014||Paul Ashton||CEO||Sell||10,000||$4.78||$47,800.00|| |
|8/1/2014||Paul Ashton||CEO||Sell||10,000||$4.37||$43,700.00|| |
|7/1/2014||Paul Ashton||CEO||Sell||10,000||$4.32||$43,200.00|| |
|6/19/2014||Paul Ashton||CEO||Sell||7,000||$4.00||$28,000.00|| |
|6/17/2014||Lori Freedman||VP||Sell||7,900||$4.00||$31,600.00|| |
|6/17/2014||Paul Ashton||CEO||Sell||7,700||$4.00||$30,800.00|| |
|6/13/2014||Lori Freedman||VP||Sell||11,700||$4.02||$47,034.00|| |
|6/13/2014||Paul Ashton||CEO||Sell||11,800||$4.02||$47,436.00|| |
|10/1/2012||Paul Hopper||Director||Buy||10,000||$1.68||$16,800.00|| |
Headline Trends for pSivida Corp. (NASDAQ:PSDV)
Latest Headlines for pSivida Corp. (NASDAQ:PSDV)
Loading headlines, please wait.
pSivida Corp. (PSDV) Chart for Tuesday, October, 24, 2017